drugset / Trial / NCT02876601

Defibrotide in the Human Endotoxemia Model --- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide

NCT02876601

Phase 4 Completed 20 enrolled Medical University of Vienna
RandomizedCrossoverQuadruple-blindBasic science

Summary

Defibrotide is an anti-inflammatory and anti-coagulatory agent approved for treatment of veno-occlusive disease. Although it has been in clinical use for almost 30 years, the exact mechanism of action has never been fully elucidated. Thus, the effects of defibrotide will be investigated in the human endotoxemia model in order to gather further information on its actions.

Timeline

Start
2017-04-18
Primary completion
2018-02-12
Completion
2018-02-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Defibrotide Oligonucleotide (other) 6.25 mg/kg Other

Indications

No indication recorded.